Company Overview - The company, Ruipai Pet Hospital Management Co., Ltd., is a national chain of pet medical institutions in China, focusing on high-standard diagnosis and health management services for pets [4] - Founded in 2012, the company aims to establish a standardized and replicable pet health management service system across the country, inspired by the professionalization and standardization seen in the U.S. pet medical industry [4][5] - As of June 30, 2025, the company is projected to be the second-largest pet medical service provider in China, operating 548 pet hospitals, including 120 self-built and 428 acquired hospitals [5] Financial Performance - The company's revenue for the fiscal years 2022, 2023, 2024, and the six months ending June 30, 2025, is approximately RMB 1.455 billion, RMB 1.585 billion, RMB 1.758 billion, and RMB 943 million respectively [6] - The total comprehensive income for the same periods shows losses of approximately RMB 61.86 million, RMB 250 million, RMB 0.7126 million, and a profit of RMB 15.28 million [7] - The gross profit margins for these years are 22.4%, 21.0%, 22.2%, and 24.8% respectively, indicating a trend of improving profitability [9] Industry Overview - The Chinese pet market is entering a high-growth phase, with the market size expected to reach RMB 300 billion by 2024 and RMB 602.5 billion by 2030, reflecting a compound annual growth rate (CAGR) of 12.3% [10] - The pet medical sector is projected to grow from RMB 36.6 billion in 2024 to RMB 69.9 billion by 2030, with a CAGR of 11.4% [12] - High-tier cities in China account for 66.7% of pet hospitals and 75.8% of total revenue in the pet medical industry, with significant growth expected in these regions [14] Shareholding Structure - Dr. Li is the largest single shareholder of the company, controlling approximately 26.91% of the issued share capital through Zhongrui Huapu and Ruipubio [18]

Core Viewpoint - The pet medical industry is a core sector of the pet economy, characterized by both rigidity and growth potential, following a development path similar to human consumption structure, transitioning from "goods to services" [2] Demand Side: Growth Potential in Penetration Rate and Average Spending - The aging of pets is leading to an increase in disease incidence, which is expected to trigger a surge in demand for pet medical services. The shorter lifespan of pets compared to humans means that changes in age structure will result in more pronounced demand shifts [3] - The significant growth in the penetration rate of prescription pet food reflects the rapid dissemination of pet medical knowledge in China. Prescription pet food, which is a "functional diet" prescribed by veterinarians for specific diseases, is increasingly being recognized by pet owners, especially during illness or recovery periods [3] Expansion Phase: Balancing Scale and Profitability - The domestic pet medical market is characterized by small revenue size and weak profitability. According to the 2023 China Pet Medical Industry White Paper, 82% of pet hospitals in China have annual revenues below 2.4 million yuan, and 71% have profit margins below 10%, with 26% currently operating at a loss [4] - Drawing from the U.S. market experience, while profitability is under pressure during the expansion phase, measures such as controlling the pace of expansion, standardized mergers and acquisitions, and refined operations can gradually enhance profitability [4] Cost Structure: Challenges in Variable Cost Optimization - In the domestic market, employee and procurement costs are the main constraints on optimizing variable costs for pet hospitals. The operating costs are primarily concentrated in labor and consumables, with a shortage of veterinary talent and low domestic procurement rates for consumables being significant challenges [5] - The long-term reliance on imports for veterinary vaccines and the dominance of foreign brands in pet medications contribute to higher procurement costs for domestic pet medical enterprises. In contrast, the U.S. has a mature local supply chain, which provides cost advantages in consumable procurement [5]